TAK-448 acetate - ≥99% , CAS No.1470374-22-1
Auf Lager
SKU
T648337
TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC 50 of 460 pM and an EC 50 of 632 pM
In Vivo
TAK-448 acetate (0.01-3 mg/kg; given i.h.; dosings on day 0 and 28) has greater anti-tumor effects in VCaP xenograft model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat VCaP xenograft androgen-sensitive prostate cancer model (7-week-old rats) Dosage: 0.01, 0.03, 0.3, 3 mg/kg Administration: Given i.h.; dosings on day 0 and 28 Result: Had greater anti-tumor effects in VCaP xenograft model.
Form:Solid
IC50& Target:IC50: 460 pM (KISS1R), EC50: 632 pM (KISS1R)
Weitere Informationen
| CAS | 1470374-22-1 |
|---|---|
| Synonyme | Q27277681 | F5X2S8T7CV | 1470374-22-1 | UNII-F5X2S8T7CV | TAK-448 acetate | TAK-448 (acetate) | HY-P0076A | MS-32089 |
| Spezifikationen & Reinheit | ≥99% |
| Storage | Desiccated,Store at -80°C |
| Verschickt in | Dry ice packs + Cold packs |
| Product Description | TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC 50 of 460 pM and an EC 50 of 632 pM In Vivo TAK-448 acetate (0.01-3 mg/kg; given i.h.; dosings on day 0 and 28) has greater anti-tumor effects in VCaP xenograft model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat VCaP xenograft androgen-sensitive prostate cancer model (7-week-old rats) Dosage: 0.01, 0.03, 0.3, 3 mg/kg Administration: Given i.h.; dosings on day 0 and 28 Result: Had greater anti-tumor effects in VCaP xenograft model. Form:Solid IC50& Target:IC50: 460 pM (KISS1R), EC50: 632 pM (KISS1R) |
| Löslichkeit | DMSO : ≥ 100 mg/mL (77.80 mM) H2O : 50 mg/mL (38.90 mM; Need ultrasonic) |
| PubChem CID | 91668185 |
Bewertungen
Kundenbewertungen
Remind me later